BioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will participate virtually in the SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 a.m. ET.

Rhea-AI Summary

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will participate virtually in the SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 a.m. ET. Company leaders, Jean-Jacques Bienaimé and Brian Mueller, will represent the firm. Investors can access the live webcast at BioMarin's investor website. An archived version will also be available for a limited time post-conference. BioMarin, founded in 1997, focuses on genetic therapies and has developed eight commercial therapies for rare genetic disorders to meet significant medical needs. For more information, visit www.biomarin.com.

Argus Session date unavailable

-0.25% session move Open Argus

Details

News Market Reaction – BMRN

The recorded move for BMRN in the trading session of this news was -0.25%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN RAFAEL, Calif., Feb. 14, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer and Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will participate virtually in the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023, at 11:20 a.m. ET.

To access the live webcast, please visit: https://investors.biomarin.com/. An archived version of the presentation will also be available through the Company's website for a limited time following the conference.

About BioMarin
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:
Investors	Media
Traci McCarty	Marni Kottle
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(650) 374-2803

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-virtually-at-svb-securities-global-biopharma-conference-on-february-16-2023-301745829.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date and time of BioMarin's participation in the SVB Securities Global Biopharma Conference?

BioMarin Pharmaceutical Inc. will participate on February 16, 2023, at 11:20 a.m. ET.

Who will represent BioMarin at the SVB Securities Global Biopharma Conference?

Jean-Jacques Bienaimé and Brian Mueller will represent BioMarin at the conference.

How can I access the BioMarin conference presentation?

The live webcast can be accessed at BioMarin's investor website: https://investors.biomarin.com/.

What is BioMarin known for regarding its product development?

BioMarin is known for developing targeted therapies for rare genetic disorders and has eight commercial therapies.

Where can I find more information about BioMarin?

More information can be found on BioMarin's website at www.biomarin.com.